CN103204827B - 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 - Google Patents

作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 Download PDF

Info

Publication number
CN103204827B
CN103204827B CN201210189087.2A CN201210189087A CN103204827B CN 103204827 B CN103204827 B CN 103204827B CN 201210189087 A CN201210189087 A CN 201210189087A CN 103204827 B CN103204827 B CN 103204827B
Authority
CN
China
Prior art keywords
alkyl
formula
compound
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210189087.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103204827A (zh
Inventor
田红旗
季聪慧
刘春磊
黄功超
孔丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kezhou Pharmaceutical Co.,Ltd.
Original Assignee
KECHOW PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201210189087.2A priority Critical patent/CN103204827B/zh
Application filed by KECHOW PHARMA Inc filed Critical KECHOW PHARMA Inc
Priority to EP13738359.2A priority patent/EP2804855B1/en
Priority to JP2014551508A priority patent/JP6077006B2/ja
Priority to US14/372,731 priority patent/US9290468B2/en
Priority to PCT/CN2013/000037 priority patent/WO2013107283A1/en
Priority to CA2897259A priority patent/CA2897259C/en
Priority to NZ627631A priority patent/NZ627631A/en
Priority to HK15103824.9A priority patent/HK1203486B/en
Priority to AU2013201455A priority patent/AU2013201455B8/en
Publication of CN103204827A publication Critical patent/CN103204827A/zh
Application granted granted Critical
Publication of CN103204827B publication Critical patent/CN103204827B/zh
Priority to US15/050,045 priority patent/US9937158B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201210189087.2A 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 Active CN103204827B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201210189087.2A CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
AU2013201455A AU2013201455B8 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US14/372,731 US9290468B2 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
PCT/CN2013/000037 WO2013107283A1 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
CA2897259A CA2897259C (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
NZ627631A NZ627631A (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
EP13738359.2A EP2804855B1 (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
JP2014551508A JP6077006B2 (ja) 2012-01-17 2013-01-16 ベンゾ複素環式化合物およびその使用
HK15103824.9A HK1203486B (en) 2012-01-17 2013-01-16 Benzoheterocyclic compounds and use thereof
US15/050,045 US9937158B2 (en) 2012-01-17 2016-02-22 Benzoheterocyclic compounds and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210014021.X 2012-01-17
CN201210014021 2012-01-17
CN201210189087.2A CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN103204827A CN103204827A (zh) 2013-07-17
CN103204827B true CN103204827B (zh) 2014-12-03

Family

ID=48752254

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201210189087.2A Active CN103204827B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
CN201210189086.8A Active CN103204822B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CN201210190520.4A Active CN103204825B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210189086.8A Active CN103204822B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CN201210190520.4A Active CN103204825B (zh) 2012-01-17 2012-06-08 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途

Country Status (7)

Country Link
US (2) US9290468B2 (enExample)
EP (1) EP2804855B1 (enExample)
JP (1) JP6077006B2 (enExample)
CN (3) CN103204827B (enExample)
CA (1) CA2897259C (enExample)
NZ (1) NZ627631A (enExample)
WO (1) WO2013107283A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710417B (zh) * 2013-12-11 2020-09-08 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN105859543A (zh) * 2016-05-06 2016-08-17 蚌埠中实化学技术有限公司 一种2,6-二氟-4-溴苯甲酰氯的制备方法
CN111205244B (zh) * 2018-11-22 2023-08-18 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
EP4663631A1 (en) * 2023-02-10 2025-12-17 Shanghai Kechow Pharma, Inc. Polymorph as protein kinase mek inhibitor, and preparation method therefor and use thereof
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025242163A1 (zh) * 2024-05-23 2025-11-27 上海科州药物股份有限公司 蛋白激酶mek抑制剂的盐及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2007121154A2 (en) * 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
CN101213196A (zh) * 2005-07-01 2008-07-02 赛诺菲-安万特 吡啶并[2,3-d]嘧啶衍生物，它们的制备，在治疗中的用途
CN101605783A (zh) * 2007-01-05 2009-12-16 赛诺菲-安万特 作为药物、药物组合物尤其作为ikk抑制剂的新型n,n’-2,4-二苯胺基嘧啶衍生物及其制备
CN101678014A (zh) * 2007-05-21 2010-03-24 Sgx药品公司 杂环激酶调节剂

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
JP2002509536A (ja) 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
JP2002511092A (ja) 1997-07-01 2002-04-09 ワーナー−ランバート・コンパニー ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用
US6120451A (en) 1998-12-31 2000-09-19 General Electric Company Ultrasound color flow display optimization by adjustment of threshold
ATE311363T1 (de) 1999-01-13 2005-12-15 Warner Lambert Co Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
AP2001002225A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CN1358094A (zh) * 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005046665A1 (en) 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
JP4869075B2 (ja) 2003-11-19 2012-02-01 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの複素環阻害剤及びその使用方法
RU2500673C2 (ru) 2005-05-18 2013-12-10 Астразенека Аб Гетероциклические ингибиторы мек и способы их применения
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
CN101341132A (zh) 2005-12-21 2009-01-07 阿斯利康(瑞典)有限公司 作为mek抑制剂用于治疗癌症的6-(4-溴-2-氯-苯基氨基)-7-氟-n-(2-羟基乙氧基)-3-甲基-3h-苯并咪唑-5-甲酰胺的甲苯磺酸盐
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
CN101454004B (zh) 2006-04-18 2013-12-04 阿迪亚生命科学公司 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
GB0625691D0 (en) 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
CA2675358C (en) 2007-01-19 2016-01-05 Ardea Biosciences, Inc. Inhibitors of mek
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
CN101678001A (zh) 2007-04-13 2010-03-24 阿斯利康(瑞典)有限公司 包含azd2171和azd6244或mek-抑制剂ⅱ的组合治疗
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
FR2918785B1 (fr) 2007-07-13 2009-11-13 Lemer Prot Anti X Par Abrevati Materiau radioattenuateur, et procede pour l'obtention d'un tel materiau
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US20100004247A1 (en) 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
FR2967672B1 (fr) 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056789A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
CN101213196A (zh) * 2005-07-01 2008-07-02 赛诺菲-安万特 吡啶并[2,3-d]嘧啶衍生物，它们的制备，在治疗中的用途
WO2007121154A2 (en) * 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
CN101605783A (zh) * 2007-01-05 2009-12-16 赛诺菲-安万特 作为药物、药物组合物尤其作为ikk抑制剂的新型n,n’-2,4-二苯胺基嘧啶衍生物及其制备
CN101678014A (zh) * 2007-05-21 2010-03-24 Sgx药品公司 杂环激酶调节剂

Also Published As

Publication number Publication date
WO2013107283A1 (en) 2013-07-25
CN103204822A (zh) 2013-07-17
CN103204822B (zh) 2014-12-03
CA2897259A1 (en) 2013-07-25
AU2013201455B2 (en) 2015-07-23
US20160235721A1 (en) 2016-08-18
US9290468B2 (en) 2016-03-22
CN103204825B (zh) 2015-03-04
CN103204825A (zh) 2013-07-17
AU2013201455A8 (en) 2016-04-14
NZ627631A (en) 2016-10-28
HK1203486A1 (en) 2015-10-30
EP2804855A1 (en) 2014-11-26
EP2804855B1 (en) 2017-09-20
JP2015503597A (ja) 2015-02-02
AU2013201455A1 (en) 2013-08-01
CA2897259C (en) 2019-05-07
EP2804855A4 (en) 2015-07-29
US9937158B2 (en) 2018-04-10
AU2013201455C1 (en) 2016-01-21
CN103204827A (zh) 2013-07-17
US20140371278A1 (en) 2014-12-18
JP6077006B2 (ja) 2017-02-08

Similar Documents

Publication Publication Date Title
CN103204827B (zh) 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
Cheng et al. Synthesis, antibacterial activities and molecular docking studies of peptide and Schiff bases as targeted antibiotics
TWI557110B (zh) 作為５－ｈｔ6拮抗劑的芳基磺醯基吡唑啉羧脒衍生物
CA2954376C (en) Novel anxiolytic compounds
TW202227397A (zh) 雙環的－雜環衍生物及相關用途
JP2013503190A (ja) Ｒａｆ阻害化合物およびその使用方法
KR20090110950A (ko) (피라진 유도체) 퀴녹살린 화합물 및 이의 용도
WO2018145621A1 (zh) 喹啉类化合物、其制备方法及其医药用途
JP2011500734A (ja) 新規なヒストンデアセチラーゼインヒビター、その調製方法および使用
JP2022509534A (ja) Ｂｅｔ阻害剤としてのヘテロ環式化合物
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
JP2013509412A (ja) 多標的キナーゼ阻害における新規な足場としてのイミダゾピリジン類
AU2020255702B2 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN107987072B (zh) 作为crth2抑制剂的吲哚类化合物
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
TW479058B (en) 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives
CN105384738B (zh) 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CA2923175C (en) Liver x receptor (lxr) modulators
Boddiboyena et al. Synthesis and biological evaluation of novel amide derivatives of 1, 2, 4-oxadiazole-imidazopyridines as anticancer agents
CN103958526B (zh) 嘧啶二胺类衍生物、其制备方法及其在医药上的应用
ES2823577T3 (es) Derivados de urea basados en pirazolilo sustituido como ligandos del receptor vainilloide
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
CN105228609A (zh) 新的转录因子调节剂
Jin et al. Design, synthesis, and evaluation of thiazolecarboxamide derivatives as stimulator of interferon gene inhibitors
CN116715613A (zh) 一种RORγ共价抑制化合物及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SHANGHAI KEZHOU PHARMACEUTICAL RESEARCH + DEVELOPM

Free format text: FORMER OWNER: BINJIANG PHARMA, INC.

Effective date: 20140821

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 300457 BINHAI NEW DISTRICT, TIANJIN TO: 201203 PUDONG NEW AREA, SHANGHAI

TA01 Transfer of patent application right

Effective date of registration: 20140821

Address after: 201203 Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road, room 714 No. 780

Applicant after: KECHOW PHARMA, Inc.

Address before: 300457 experimental building, Tianjin international biological medicine Joint Research Institute, 220 Dongting Road, Tianjin Binhai New Area Development Zone, N1701

Applicant before: TIANJIN BINJIANG PHARMACEUTICAL Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address

Address after: Room 714, No. 780 Cailun Road, Zhangjiang High tech Park, Pudong New Area, Shanghai, 201203

Patentee after: Shanghai Kezhou Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: Room 714, No. 780 Cailun Road, Zhangjiang High tech Park, Pudong New Area, Shanghai, 201203

Patentee before: KECHOW PHARMA, Inc.

Country or region before: China

CP03 Change of name, title or address